New study links immune-related thyroid issues to improved outcomes in patients with advanced non-small cell lung cancer. Non-Small Cell Lung Cancer: An Ongoing Challenge Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung […]
Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]
Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]
Copyright (c) 2021 Association of Basic Medical Sciences of FBIH